Stocks · Health care · Pharmaceutical Preparations

Dyne Therapeutics, Inc.

DYN Clue Score43
United States Fiscal year ends December CIK 0001818794 Results filed 5 Nov 2026

What the insiders did No buying or selling

By person

11 insiders · 0 transactions
9.5×

John G. Cox holds 9.5 times base salary in stock. $6.87M of shares against $721.00K in salary for 2025.

Salary from the company's own proxy. The shares are what John G. Cox last reported holding, valued at $16.00, the price Common Stock was last bought or sold at on the open market here, on 2 Oct 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Dirk Kersten
Director
—
—
—
3,586,796
1.92%
$57.39M
−38.9%
John Cox
CEO & President
—
—
—
429,507
0.2300%
$6.87M
+457.8%
Jason P Rhodes
Director
—
—
—
428,946
0.2297%
$6.86M
−91.4%
Oxana Beskrovnaya
Chief Scientific Officer
—
—
—
195,840
0.1049%
$3.13M
+39.5%
Douglas Kerr
Head of R&D and CMO
—
—
—
170,564
0.0913%
$2.73M
+259.1%
Johanna Friedl-Naderer
Chief Commercial Officer
—
—
—
152,897
0.0819%
$2.45M
+161.8%
Richard William Scalzo
SVP, Head of Finance & Admin.
—
—
—
122,330
0.0655%
$1.96M
+24.1%
Erick Lucera
Chief Financial Officer
—
—
—
119,766
0.0641%
$1.92M
—
Brian S Posner
Director
—
—
—
27,000
0.0145%
$432.00K
+217.6%
David Charles Lubner
Director
—
—
—
0
0.0000%
$0.00
−100.0%
Carlo Incerti
Director
—
—
—
0
0.0000%
$0.00
—